BIO-TECHNE TO PRESENT AT THE CREDIT SUISSE 31ST ANNUAL HEALTHCARE CONFERENCE

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the Credit Suisse 31^st Annual Healthcare Conference on November 9, 2022, at 8:35 a.m. PST. A live webcast will be available on the company's Investor Relations website.

Bio-Techne specializes in manufacturing purified proteins and reagent solutions, generating approximately $1.1 billion in net sales in fiscal 2022, with around 3,000 employees globally. Its diverse portfolio supports biomedical researchers and clinical laboratories.

MINNEAPOLIS, Nov. 3, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Credit Suisse 31^st Annual Healthcare Conference on Wednesday, November 9, 2022, at 8:35 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000 employees worldwide.

Contact:	David Clair, Vice President, Investor Relations
	david.clair@bio-techne.com
	612-656-4416

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-credit-suisse-31st-annual-healthcare-conference-301667351.html

SOURCE Bio-Techne Corporation

FAQ

When is Bio-Techne presenting at the Credit Suisse 31st Annual Healthcare Conference?

Bio-Techne will present on November 9, 2022, at 8:35 a.m. PST.

Who is the CEO of Bio-Techne?

Chuck Kummeth is the CEO of Bio-Techne Corporation.

Where can I watch the Bio-Techne conference presentation?

The presentation will be available via a live webcast on Bio-Techne's Investor Relations website.

What are Bio-Techne's primary business segments?

Bio-Techne operates in two main segments: Protein Sciences and Diagnostics and Genomics.

What was Bio-Techne's net sales for fiscal 2022?

Bio-Techne generated approximately $1.1 billion in net sales for fiscal 2022.